This test is most useful if any of these apply to you.
Say your routine bloodwork has shown low alkaline phosphatase (ALP) more than once, and you've also had a fracture that wouldn't heal, persistent bone or joint pain, or teeth that came out too early. Urine phosphoethanolamine (PEA) can help investigate whether hypophosphatasia explains that pattern. This inherited condition reduces the activity of an enzyme needed for bones and teeth to harden.
Urine PEA is an established supporting test in that workup. Diagnosis brings together your symptoms, ALP results, imaging and, when appropriate, ALPL genetic testing. A raised PEA result strengthens the case in the right setting, but other conditions can raise it and some people with hypophosphatasia have an unremarkable result.
Phosphoethanolamine is made from ethanolamine with a phosphate group attached. Your cells use it to make membrane fats, and it also appears during their breakdown. Small amounts are normally present in urine.
The form of ALP involved in hypophosphatasia is called tissue-nonspecific alkaline phosphatase. It's found in bone, liver and kidney tissue and can remove phosphate from PEA. It also acts on pyridoxal 5'-phosphate (PLP) and inorganic pyrophosphate. PLP is an active form of vitamin B6. Pyrophosphate limits the formation of mineral crystals, so its accumulation interferes with the hardening of bones and teeth.
These substances can accumulate when this enzyme's activity is reduced, though they don't all rise in every affected person. The exact processes responsible for PEA accumulation are still incompletely understood, and the amount in urine isn't a direct measurement of bone strength.
This test quantifies PEA in a random urine sample using LC-MS/MS. The method separates molecules and identifies them by their mass. The result is reported relative to urine creatinine, usually as nmol/mg creatinine. Dividing by creatinine helps account for urine dilution, but differences in creatinine production and excretion can still affect the ratio.
Hypophosphatasia is usually shortened to HPP. Disease-causing changes in the ALPL gene reduce the enzyme's activity. In children, HPP can cause rickets and early loss of baby teeth. Adults may have poorly healing fractures, persistent muscle and bone pain, calcium crystal deposits in joints, and dental problems. Some develop osteomalacia. In this condition, bone doesn't harden properly because it contains too little mineral.
A single-center study of 78 adults referred for possible HPP found that untreated cases had a median urine PEA roughly eight times that of people whose HPP diagnosis was excluded. That study used ion-exchange chromatography to separate and quantify urine PEA. Its diagnostic performance figures describe that assay and selected clinic population.
| Who Was Studied | What Was Compared | What They Found |
|---|---|---|
| 78 adults referred for possible HPP | Urine PEA, blood ALP and blood PLP | PEA separated the groups best in this cohort. The study's decision rule detected about 88% of untreated cases, with no false positives among 19 comparison participants; this doesn't establish perfect specificity in routine use. |
| 77 adults with persistently low ALP | Prediction models combining ALP with urine PEA or blood PLP | In a small internal validation sample, the PLP model detected all disease-causing variant carriers, while the PEA model detected about 71%. These were model results, not the accuracy of either test alone. |
| 22 adults diagnosed with HPP in a clinical series | How often urine PEA was raised among those tested | PEA was raised in 15 of 16 tested. Raised PEA was itself one possible inclusion criterion, which limits its value as an independent estimate of sensitivity. |
The 77-person study measured urine PEA by LC-MS/MS and looked for disease-causing ALPL variants. The referral study assessed a clinical HPP diagnosis. Their different populations, assays and definitions help explain why the tests ranked differently. Neither study establishes one marker as the best test for every person.
Urine PEA can remain within a laboratory's expected range in people with HPP, particularly those with milder disease. In a separate study of 42 adults with unexplained low ALP, half had an ALPL variant, yet only one participant had raised urine PEA. That study used liquid chromatography with fluorescence detection, a different analytical method from this test. Many participants had few symptoms.
PEA therefore provides supporting evidence without reliably excluding HPP. A repeatedly low ALP and a history of characteristic fractures or early tooth loss still deserve evaluation even when urine PEA isn't raised. The urine number also cannot reliably predict how severe the disease will be.
Some people have an ALPL variant and a biochemical pattern associated with HPP while feeling well. A database study selected 43 people with low ALP, at least one ALPL variant, and no reported HPP symptoms. Nineteen also had raised PLP or PEA. Because low ALP was required for inclusion, this study doesn't show that every person with an ALPL variant has low ALP.
A biochemical finding alone doesn't establish symptomatic bone disease or a need for treatment. The same variant can be associated with different symptoms, including no apparent symptoms. The urine result also cannot establish which relatives inherited a variant; that requires genetic testing.
Exploratory human studies have found increased urine PEA during acute kidney injury. One study also found differences between injury to kidney tubules and a temporary reduction in kidney blood flow. A separate small heart-surgery study associated preoperative urine PEA with subsequent kidney injury. These studies used research measurements of urinary PEA, but they haven't established this test as a routine way to diagnose or predict kidney injury.
Genetic research has linked variation near ALPL to both urinary PEA and kidney stones. In that analysis, the stone-associated variant was linked to lower urinary PEA, consistent with greater enzyme activity. This supports a possible connection between phosphate handling and stone formation, but it doesn't establish PEA itself as a cause of stones or provide a urine PEA target for preventing them.
A raised result has several possible explanations. Older studies of urine PEA documented variation with diet, time of day and age, as well as elevations in conditions other than HPP.
The companion ALP and PLP results have their own confounders. Some medicines and nutritional deficiencies lower ALP without HPP, while vitamin B6 supplements can raise PLP. Those effects need to be separated from changes in urinary PEA.
Serial urine PEA can contribute to specialist follow-up, but the size of a change hasn't been established as a reliable measure of fracture healing, symptom improvement or disease progression. There is no validated urine PEA treatment target that predicts those outcomes. Symptoms, physical function and imaging remain part of the assessment.
Evidence-backed interventions that affect your Phosphoethanolamine level
Phosphoethanolamine is best interpreted alongside these tests.
Phosphoethanolamine is included in these pre-built panels.
A comprehensive at-home nutritional and metabolic assessment that analyzes key biomarkers to reveal functional nutrient needs and imbalances.